Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced on October 8 that the company received a Drug Registration Certificate from China's National Medical Products Administration for its sacubitril/valsartan sodium tablets in October 2026, with the review conclusion being approval for registration.
The company submitted its marketing authorization application materials for the sacubitril/valsartan sodium tablets to the Center for Drug Evaluation of the National Medical Products Administration in April 2025 and received acceptance at that time, according to the announcement.
Source: Caijing (Financial News)